Tricida (NASDAQ:TCDA – Get Rating) and Kronos Bio (NASDAQ:KRON – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Profitability

This table compares Tricida and Kronos Bio's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Tricida and Kronos Bio, as reported by MarketBeat.com.

Institutional and Insider Ownership

62.6% of Kronos Bio shares are held by institutional investors. 35.6% of Tricida shares are held by company insiders. Comparatively, 28.2% of Kronos Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Tricida and Kronos Bio's revenue, earnings per share and valuation.

Kronos Bio is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tricida has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Kronos Bio beats Tricida on 6 of the 11 factors compared between the two stocks.

About Tricida

(Get Rating)

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

About Kronos Bio

(Get Rating)

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, is a next-generation SYK inhibitor for treatment of autoimmune disease. Kronos Bio, Inc. was incorporated in 2017 and is headquartered in San Mateo, California.

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.